New heart failure drug tested in 2,400 chinese patients
NCT ID NCT05728502
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study collected data from 2,400 adults in China with chronic heart failure to see how well the drug vericiguat works compared to standard treatments. Researchers tracked deaths, hospital stays, and side effects over 12 months. The goal is to understand if vericiguat helps control the disease better in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese Registries
Multiple Locations, Many Locations, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heart failure drug puzzle: study aims to untangle polypharmacy risks
- Salt pills for heart failure? new study investigates
- Smartphone app may help heart failure patients get the right meds faster
- Which workout is best for heart failure? new study aims to find out
- Could a common steroid speed heart shock recovery?
- Smart alerts aim to cut heart failure hospital stays